TC
TScan Therapeutics, Inc.
TCRX · NASDAQ
$0.33 -2.28% (-$0.01)
1M -58.64%
Market Cap $20.2M
P/E Ratio -
Div. Yield -
ROE 108.72%
Bulios Fair Price
$0.49
48.2% upside
Trenutna cena
$0.33
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica TCRX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
81 /100
Cheap P/B 0.29x
P/S 2.84x
EV/EBITDA N/A
Growth
14 /100
Declining Book val. growth 7.38%
Rev. growth 8.63%
FCF growth N/A
Profitability
20 /100
Weak Net margin 1,655.35%
Op. margin 1,695.15%
FCF margin 1,665.57%
Quality
0 /100
Poor ROE 108.72%
ROA 68.66%
Asset turnover 0.04x
Debt
42 /100
Moderate Current ratio 3.37x
Int. coverage -41.21x
Debt/Equity 1.32x
Stability
46 /100
Moderate Rev. volatility 177.76%
EPS volatility 20.95%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o TCRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gavin MacBeath
Employees
138
Headquarters
Waltham
Prihajajoči dogodki
11 NOV.
Earnings
Upcoming earnings report